Novartis A/S (NYSE:NVS) on Thursday shared final results from the APPLAUSE-IgAN Phase 3 study evaluating Fabhalta (iptacopan) in adults with IgA nephropathy (IgAN).

NVS is in positive territory. See the complete data here

IgA nephropathy, also known as Berger's disease, is an autoimmune kidney disease in which clumps of antibodies, specifically immunoglobulin A (IgA), accumulate in the kidney's filters, leading to inflammation and damage.

Fabhalta demonstrated statistically significant, clinically meaningful superiority compared to placebo in slowing IgAN progression measured by annualized total slope of estimated glomerular filtration rate (eGFR) decline over two years. 

Also Read: Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies

eGFR is a blood test that estimates how well the kidneys are filtering waste from the blood.

In APPLAUSE-IgAN, Fabhalta was well tolerated with a favorable safety profile in line with previously ...